



## Circulating Pro- and Anti-angiogenic Factors in Cardiovascular Disorders

Guest Editor:

**Dr. Paweł Maga**

Department of Angiology, Faculty of Medicine, Jagiellonian University Medical College, Krakow, Poland

Deadline for manuscript submissions:

**closed (30 September 2023)**

### Message from the Guest Editor

Angiogenesis is a process strictly regulated and modulated by the microenvironment and multiple pro- and antiangiogenic factors. Proper angiogenesis is the result of the balance between factors inducing and inhibiting it. The disturbance in this equipoise may lead to life-threatening vascular-related diseases influencing patients' life quality. An increasingly better understanding of angiogenesis and the factors affecting this process leads to the development of new, personalized therapies focused on ischemic diseases as well as those related to overintense angiogenesis, such as rheumatoid arthritis, psoriasis or neoplasms. In the last decade, therapeutic angiogenesis is gathering more and more scientific attention in the field of ischemic tissue treatment due to the stimulation of new vascular vessel creation based on existing vascular systems.

In this Special Issue, *in vitro* and *in vivo* studies, original research and reviews are all welcome.





an Open Access Journal by MDPI

## Editor-in-Chief

### Prof. Dr. Felipe Fregni

1. Neuromodulation Center and  
Center for Clinical Research  
Learning, Spaulding  
Rehabilitation Hospital and  
Massachusetts General Hospital,  
Harvard Medical School, Boston,  
MA 02114, USA  
2. Department of Epidemiology,  
Harvard T.H. Chan School of  
Public Health, Boston, MA 02115,  
USA

## Message from the Editor-in-Chief

*Biomedicines* (ISSN 2227-9059) is an open access journal devoted to all aspects of research on human health and disease, the discovery and characterization of new therapeutic targets, therapeutic strategies, and research of naturally driven biomedicines, pharmaceuticals, and biopharmaceutical products. Topics include pathogenesis mechanisms of diseases, translational medical research, biomaterial in biomedical research, natural bioactive molecules, biologics, vaccines, gene therapies, cell-based therapies, targeted specific antibodies, recombinant therapeutic proteins, nanobiotechnology driven products, targeted therapy, bioimaging, biosensors, biomarkers, and biosimilars. The journal is open for publication of studies conducted at the basic science and preclinical research levels. We invite you to consider submitting your work to *Biomedicines*, be it original research, review articles, or developing Special Issues of current key topics.

## Author Benefits

**Open Access:** free for readers, with article processing charges (APC) paid by authors or their institutions.

**High Visibility:** indexed within *Scopus*, *SCIE (Web of Science)*, *PubMed*, *PMC*, *CAPLus / SciFinder*, and other databases.

**Journal Rank:** JCR - Q1 (Pharmacology and Pharmacy) / CiteScore - Q1 (Medicine (miscellaneous))

## Contact Us

*Biomedicines* Editorial Office  
MDPI, Grosspeteranlage 5  
4052 Basel, Switzerland

Tel: +41 61 683 77 34  
[www.mdpi.com](http://www.mdpi.com)

[mdpi.com/journal/biomedicines](http://mdpi.com/journal/biomedicines)  
[biomedicines@mdpi.com](mailto:biomedicines@mdpi.com)  
[X@Biomed\\_MDPI](https://twitter.com/Biomed_MDPI)